FilingReader Intelligence

Syngene receives USFDA clearance; legal head resigns

June 27, 2025 at 09:03 AM UTCBy FilingReader AI

Syngene International (BSE: SYNGENE) announced that it has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its GMP manufacturing facilities located at Biocon Park, Bengaluru, following an inspection conducted between February 10 and February 20, 2025. The USFDA classified the inspectional outcome as Voluntary Action Indicated (VAI), indicating that the FDA has reviewed and accepted Syngene’s corrective action plans submitted in response to the inspection findings.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Syngene International publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →